DoriNano, a Massachusetts-based biotech company led by Massachusetts Next Generation (MassNextGen) Initiative Alum Yang (Claire) Zeng, MD, PhD, has entered into a research collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute Boston to evaluate applications of its nanotechnology platform for nucleic acid delivery.
Under this partnership, scientists from DoriNano and the Daiichi Sankyo Research Institute Boston will engage in a two-year research collaboration to assess the programmability, structural precision, and biological performance of DoriNano’s DNA origami-based nanoparticle platform in a research setting, including its potential to deliver novel nucleic acid-based cargo to undisclosed targets.
Since inception, the MassNextGen Initiative has supported 39 companies across its portfolio. Non-dilutive funding from the MLSC combined with executive coaching and business mentorship in addition to in-kind lab bench space continues to prove invaluable for MassNextGen entrepreneurs in building their teams and progressing their innovative treatments and technologies forward. The program continues to drive expansion and growth for these early-stage companies, including 19 awardees who have raised a Seed or Series A financing round. Collectively, MassNextGen companies have raised over $401 million in follow-on funding.
Applications for the latest round of the MassNextGen Initiative open on March 16, 2026. Click here to learn more and register for an upcoming info session.
